News
09-25-2011, 10:28 PM
Afinitor (evelolimus), a Novartis kidney cancer drug, when combined with hormonal therapy doubled breast cancer patients' progression-free survival, and reduced cancer progression risk by 57% compared to exemestane alone, researchers revealed during a Presidential Symposium at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden...
More... (http://www.medicalnewstoday.com/articles/234983.php)
More... (http://www.medicalnewstoday.com/articles/234983.php)